VNOVOTCWholesale-Apparel, Piece Goods & NotionsFiscal year ends April 30
VitaNova Life Sciences Corp
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$4.50+0.50 (+12.50%)
Close on Oct 19, 2026
- Market cap
- $37.52M
- P/E (TTM)
- –
- Dividend yield
- –
VitaNova Life Sciences Corp revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Dietary Supplement Segment [Member] | $1.95M | $2.65M | – | – | 64.4% | -26.5% |
| Food Products [Member] | $1.06M | – | – | – | 35.1% | – |
| Other [Member] | $15.00K | – | – | – | 0.5% | – |
| Consulting Service Segment [Member] | – | $10.84K | $26.10K | $38.00K | – | – |
| Healthcare Segment [Member] | – | $2.65M | $544.59K | $0 | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | YoY |
|---|---|---|---|---|---|
| Dietary Supplement Segment [Member] | $168.07K | $1.48M | – | – | -88.6% |
| Other [Member] | $15.00K | – | – | – | – |
| Food Products [Member] | -$179.47K | – | – | – | – |
| Consulting Service Segment [Member] | – | -$270.72K | -$103.27K | -$24.23K | – |
| Healthcare Segment [Member] | – | $1.48M | $308.90K | $0 | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Dietary Supplement Products [Member] | $1.95M | $2.65M | – | – | 64.4% | -26.5% |
| Sale Of Food Products [Member] | $1.06M | – | – | – | 35.1% | – |
| Consulting Service Income [Member] | $15.00K | $10.84K | $26.10K | $38.00K | 0.5% | +38.4% |
| Sale Of Healthcare Products [Member] | – | $2.65M | $544.59K | – | – | – |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Unites States Of America [Member] | $2.68M | $1.20M | $77.85K | $38.00K | 88.6% | +122.6% |
| Hong Kong SAR China | $345.58K | $1.07M | $81.75K | $0 | 11.4% | -67.8% |
| China | $0 | $385.72K | $411.10K | $0 | 0.0% | -100.0% |
From the segment and revenue-disaggregation notes of VitaNova Life Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.